AEGiS-14IAC: Hepatotoxicity due to latent tuberculous infection treatment as a marker for hepatopathy.

14th International AIDS Conference


Barcelona, Spain - July 7-12, 2002

DonateNow
Print this article

Hepatotoxicity due to latent tuberculous infection treatment as a marker for hepatopathy.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. B10241)

Aldamiz M, Portu J, Martin MJ, Almaraz MJ, Pinedo A, Salazar A, Barroso J
Hospital Txagorritxu, Vitoria, Spain

BACKGROUND: The interruption of latent tuberculous infection (ITLB) due to hepatotoxicity is a frequent fact in patients with HIV infection. Our objective is to check if the interruption of the treatment due to hepatotoxicity represents a marker for hepatopathy. Patients and

METHODS: 438 patients with HIV infection started ITLB. 66.4% (n=291) finished correctly and 33.6% (n=147) stopped ITLB. Out of the ones who stopped, 53.1% (n= 78) did so due to adverse effects and 46.9% (n=69) due to withdrawal.

RESULTS: Of the 78 patients who stopped due to adverse effects, 53.8% (n=42) did so due to hepatotoxicity and 46.2% (n=36) for other reasons. 7.1% (n=3) of the 42 patients with ITLB hepatotoxicity and 5.6% (n=2) of the 36 patients with a withdrawal for other reasons were later diagnosed as chronic hepatopathy, without significant differences between the two.

CONCLUSIONS: hepatotoxicity induced by latent tuberculous infection treatment does not constitute a predictor for future hepatopathy diagnosis.

Keywords: AEGIS, Liver Diseases, Biological Markers, Communicable Diseases, Liver Function Tests, HIV Infections, Drug Therapy, Combination, Human, therapy, adverse effects, toxicity, drug therapyKWDaegis,liverdiseases,biologicalmarkers,communicablediseases,liverfunctiontests,hivinfections,drugtherapy,combination,human,therapy,adverseeffects,toxicity,drugtherapy

020707
B10241

Copyright © 2002 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.